UK seeks input on guidance on non-CE-marked devices for use in flu pandemic
This article was originally published in RAJ Devices
The UK Medicines and Healthcare products Regulatory Agency is asking stakeholders for details of specific issues they would like to be included in guidance the agency is developing on the use of non-CE-marked medical devices during an influenza pandemic1. Responses are due by 20 March.
You may also be interested in...
The loss of fast-track status for setmelanotide at the European Medicines Agency means the review of the potential treatment of two rare genetic disorders of obesity will take longer than Rhythm Pharmaceuticals had originally hoped.
Swiss company Santhera's lengthy and problem-laden journey to repurpose its already marketed idebenone for use in Duchenne Muscular Dystrophy has ended in failure. The company has withdrawn its EU filing for the product following its announcement that it was halting development.
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.